scispace - formally typeset
F

Francesco Cipollone

Researcher at University of Chieti-Pescara

Publications -  228
Citations -  9635

Francesco Cipollone is an academic researcher from University of Chieti-Pescara. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 49, co-authored 195 publications receiving 8335 citations. Previous affiliations of Francesco Cipollone include University of Rome Tor Vergata & University of Messina.

Papers
More filters
Journal ArticleDOI

Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register

Raffaella Rossio, +358 more
- 23 Aug 2019 - 
TL;DR: The prevalence and types of infections in a large cohort of older hospitalized patients in the frame of REPOSI, a collaborative register that involves a large number of Italian internal medicine and geriatric wards, were observed and described.
Journal ArticleDOI

Common Clinical and Molecular Pathways between Migraine and Sarcoidosis

Claudio Tana, +8 more
- 01 May 2023 - 
TL;DR: Migraines and sarcoidosis are two distinct medical conditions that may have some common biological and clinical pathways as discussed by the authors , and there is also evidence to suggest an interplay of environmental and genetic factors playing a role in both conditions.
Journal ArticleDOI

Real-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study

Mario Di Gioacchino, +9 more
- 01 Dec 2022 - 
TL;DR: In this paper , a retrospective cohort study was conducted to assess the effectiveness and safety of carbamylated monomeric allergoid subcutaneous immunotherapy (MA-SCIT), along with patient satisfaction.
Journal ArticleDOI

The challenge of lipid-modifying therapies in the achievement of optimal LDL-C levels in high and very high CV risk patients: Still an open question

Ilaria Rossi, +8 more
- 01 Aug 2022 - 
TL;DR: In this paper , the authors evaluated the efficacy of the currently available lipid lowering therapy (LLT) and the achievement of treatment targets (TT) in a cohort of high and very-high CV risk patients treated with maximum tolerated LLT.
Journal ArticleDOI

The Renin-Angiotensin System in Cardiovascular and Renal Disease

Theodore W. Kurtz, +28 more
- 01 Jun 2004 -